Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial | HIV | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
United Nations Office on Drugs and Crime. World drug report 2015. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. Published 2015. Accessed October 21. 2019.
2.
Ahrnsbrak  R, Bose  J, Hedden  SL, Lipari  RN, Park-Lee  E. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the united states: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). https://www.samhsa.gov/data/report/key-substance-use-and-mental-health-indicators-united-states-results-2016-national-survey. Published 2017. Accessed October 21, 2019.
3.
Coffin  PO. National drug early warning system (NDEWS) San Francisco sentinel community site drug use patterns and trends, 2016. https://ndews.umd.edu/sites/ndews.umd.edu/files/u1424/san_francisco_scs_drug_use_patterns_and_trends_2016.pdf. Published 2016. Accessed October 21, 2019.
4.
Shoptaw  S, Peck  J, Reback  CJ, Rotheram-Fuller  E.  Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment.  J Psychoactive Drugs. 2003;35(suppl 1):161-168. doi:10.1080/02791072.2003.10400511PubMedGoogle ScholarCrossref
5.
Tominaga  GT, Garcia  G, Dzierba  A, Wong  J.  Toll of methamphetamine on the trauma system.  Arch Surg. 2004;139(8):844-847. doi:10.1001/archsurg.139.8.844PubMedGoogle ScholarCrossref
6.
Centers for Disease Control and Prevention (CDC).  Increasing morbidity and mortality associated with abuse of methamphetamine—United States, 1991-1994.  MMWR Morb Mortal Wkly Rep. 1995;44(47):882-886.PubMedGoogle Scholar
7.
Maxwell  JC.  Emerging research on methamphetamine.  Curr Opin Psychiatry. 2005;18(3):235-242. doi:10.1097/01.yco.0000165592.52811.84PubMedGoogle ScholarCrossref
8.
U.S. Department of Health & Human Services Substance Use and Mental Health Services Administration. Amphetamine and methamphetamine emergency department visits, 1995-2002. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.187.6444&rep=rep1&type=pdf. Published July 2004. Accessed February 22, 2007.
9.
Brecht  ML, Greenwell  L, Anglin  MD.  Methamphetamine treatment: trends and predictors of retention and completion in a large state treatment system (1992-2002).  J Subst Abuse Treat. 2005;29(4):295-306. doi:10.1016/j.jsat.2005.08.012PubMedGoogle ScholarCrossref
10.
Meredith  CW, Jaffe  C, Ang-Lee  K, Saxon  AJ.  Implications of chronic methamphetamine use: a literature review.  Harv Rev Psychiatry. 2005;13(3):141-154. doi:10.1080/10673220591003605PubMedGoogle ScholarCrossref
11.
Curtis  EK.  Meth mouth: a review of methamphetamine abuse and its oral manifestations.  Gen Dent. 2006;54(2):125-129.PubMedGoogle Scholar
12.
Saini  T, Edwards  PC, Kimmes  NS, Carroll  LR, Shaner  JW, Dowd  FJ.  Etiology of xerostomia and dental caries among methamphetamine abusers.  Oral Health Prev Dent. 2005;3(3):189-195.PubMedGoogle Scholar
13.
Williams  N, Covington  JS  III.  Methamphetamine and meth mouth: an overview.  J Tenn Dent Assoc. 2006;86(4):32-35.PubMedGoogle Scholar
14.
Nicosia  N, Pacula  RL, Kilmer  B, Lundberg  R, Chiesa  J. The economic cost of methamphetamine use in the United States, 2005. https://www.rand.org/pubs/monographs/MG829.html. Published 2009. Accessed November 5, 2009.
15.
Ober  A, Shoptaw  S, Wang  PC, Gorbach  P, Weiss  RE.  Factors associated with event-level stimulant use during sex in a sample of older, low-income men who have sex with men in Los Angeles.  Drug Alcohol Depend. 2009;102(1-3):123-129. doi:10.1016/j.drugalcdep.2009.02.002PubMedGoogle ScholarCrossref
16.
Rawstorne  P, Digiusto  E, Worth  H, Zablotska  I.  Associations between crystal methamphetamine use and potentially unsafe sexual activity among gay men in Australia.  Arch Sex Behav. 2007;36(5):646-654. doi:10.1007/s10508-007-9206-zPubMedGoogle ScholarCrossref
17.
Koblin  BA, Murrill  C, Camacho  M,  et al.  Amphetamine use and sexual risk among men who have sex with men: results from the National HIV Behavioral Surveillance study—New York City.  Subst Use Misuse. 2007;42(10):1613-1628. doi:10.1080/10826080701212519PubMedGoogle ScholarCrossref
18.
Plankey  MW, Ostrow  DG, Stall  R,  et al.  The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study.  J Acquir Immune Defic Syndr. 2007;45(1):85-92. doi:10.1097/QAI.0b013e3180417c99PubMedGoogle ScholarCrossref
19.
Taylor  MM, Aynalem  G, Smith  LV, Montoya  J, Kerndt  P.  Methamphetamine use and sexual risk behaviours among men who have sex with men diagnosed with early syphilis in Los Angeles County.  Int J STD AIDS. 2007;18(2):93-97. doi:10.1258/095646207779949709PubMedGoogle ScholarCrossref
20.
Semple  SJ, Zians  J, Strathdee  SA, Patterson  TL.  Sexual marathons and methamphetamine use among HIV-positive men who have sex with men.  Arch Sex Behav. 2009;38(4):583-590. doi:10.1007/s10508-007-9292-yPubMedGoogle ScholarCrossref
21.
Karila  L, Weinstein  A, Aubin  H-J, Benyamina  A, Reynaud  M, Batki  SL.  Pharmacological approaches to methamphetamine dependence: a focused review.  Br J Clin Pharmacol. 2010;69(6):578-592. doi:10.1111/j.1365-2125.2010.03639.xPubMedGoogle ScholarCrossref
22.
Kampman  KM.  The search for medications to treat stimulant dependence.  Addict Sci Clin Pract. 2008;4(2):28-35. doi:10.1151/ascp084228PubMedGoogle ScholarCrossref
23.
Morley  KC, Cornish  JL, Faingold  A, Wood  K, Haber  PS.  Pharmacotherapeutic agents in the treatment of methamphetamine dependence.  Expert Opin Investig Drugs. 2017;26(5):563-578. doi:10.1080/13543784.2017.1313229PubMedGoogle ScholarCrossref
24.
Quitkin  FM, Taylor  BP, Kremer  C.  Does mirtazapine have a more rapid onset than SSRIs?  J Clin Psychiatry. 2001;62(5):358-361. doi:10.4088/JCP.v62n0509PubMedGoogle ScholarCrossref
25.
Nutt  DJ.  Tolerability and safety aspects of mirtazapine.  Hum Psychopharmacol. 2002;17(suppl 1):S37-S41. doi:10.1002/hup.388PubMedGoogle ScholarCrossref
26.
Mann  JJ.  The medical management of depression.  N Engl J Med. 2005;353(17):1819-1834. doi:10.1056/NEJMra050730PubMedGoogle ScholarCrossref
27.
Devoto  P, Flore  G, Pira  L, Longu  G, Gessa  GL.  Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex.  Eur J Pharmacol. 2004;487(1-3):105-111. doi:10.1016/j.ejphar.2004.01.018PubMedGoogle ScholarCrossref
28.
Nakayama  K, Sakurai  T, Katsu  H.  Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.  Brain Res Bull. 2004;63(3):237-241. doi:10.1016/j.brainresbull.2004.02.007PubMedGoogle ScholarCrossref
29.
Haddjeri  N, Blier  P, de Montigny  C.  Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission.  J Affect Disord. 1998;51(3):255-266. doi:10.1016/S0165-0327(98)00223-7PubMedGoogle ScholarCrossref
30.
Colfax  GN, Santos  GM, Das  M,  et al.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial.  Arch Gen Psychiatry. 2011;68(11):1168-1175. doi:10.1001/archgenpsychiatry.2011.124PubMedGoogle ScholarCrossref
31.
First  MB, Spitzer  RL, Gibbon  M, Williams  J.  Structured Clinical Interview for DSM-IV-TR Axis I Disorders—Non-Patient Edition (SCID-I/NP, 1/2007 revision). New York: New York State Psychiatric Institute; 2007.
32.
Brief  D, Bollinger  A, Horton  G, LoCastro  JS.  Relapse Prevention Treatment for Cocaine Addiction: the RPT-C Manual. Bethesda, MD: Medication Development Division, National Institute on Drug Abuse; 1998.
33.
Miller  W, Rollnick  S.  Motivational Interviewing. 2nd ed. New York, NY: Guilford Press; 2002.
34.
Miller  WR.  Motivational interviewing with problem drinkers.  Behav Psychother. 1983;11:147-172. doi:10.1017/S0141347300006583Google ScholarCrossref
35.
DiClemente  CC, Prochaska  JO, Gilbertini  M.  Self-efficacy and the stages of self change in smoking.  Cognit Ther Res. 1985;9:181-200. doi:10.1007/BF01204849Google ScholarCrossref
36.
Haberer  JE, Kahane  J, Kigozi  I,  et al.  Real-time adherence monitoring for HIV antiretroviral therapy.  AIDS Behav. 2010;14(6):1340-1346. doi:10.1007/s10461-010-9799-4PubMedGoogle ScholarCrossref
37.
Division of AIDS—National Institute of Allergy and Infectious Diseases. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Published 2009. Accessed October 21, 2019.
38.
Mezinskis  JDS, Goldsmith  J, Cohen  M, Somoza  E.  Craving and withdrawal symptoms for various drugs of abuse.  Psychiatr Ann. 1998;28(10):577-583. doi:10.3928/0048-5713-19981001-08Google ScholarCrossref
39.
Hartz  DTF-OS, Frederick-Osborne  SL, Galloway  GP.  Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis.  Drug Alcohol Depend. 2001;63(3):269-276. doi:10.1016/S0376-8716(00)00217-9PubMedGoogle ScholarCrossref
40.
Derogatis  LRMN, Melisaratos  N.  The brief symptom inventory: an introductory report.  Psychol Med. 1983;13(3):595-605. doi:10.1017/S0033291700048017PubMedGoogle ScholarCrossref
41.
Gossop  M, Darke  S, Griffiths  P,  et al.  The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users.  Addiction. 1995;90(5):607-614. doi:10.1046/j.1360-0443.1995.9056072.xPubMedGoogle ScholarCrossref
42.
Soldatos  CR, Dikeos  DG, Paparrigopoulos  TJ.  The diagnostic validity of the Athens Insomnia Scale.  J Psychosom Res. 2003;55(3):263-267. doi:10.1016/S0022-3999(02)00604-9PubMedGoogle ScholarCrossref
43.
Cheng  STCA, Chan  AC, Fung  HH.  Factorial structure of a short version of the Center for Epidemiologic Studies Depression Scale.  Int J Geriatr Psychiatry. 2006;21(4):333-336. doi:10.1002/gps.1467PubMedGoogle ScholarCrossref
44.
Hsieh  FY, Bloch  DA, Larsen  MD.  A simple method of sample size calculation for linear and logistic regression.  Stat Med. 1998;17(14):1623-1634. doi:10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-SPubMedGoogle ScholarCrossref
45.
McCann  DJ, Li  SH.  A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial.  CNS Neurosci Ther. 2012;18(5):414-418. doi:10.1111/j.1755-5949.2011.00263.xPubMedGoogle ScholarCrossref
46.
United Nations AIDS Program. Undetectable=untransmissible: public health and viral load suppression. https://www.unaids.org/sites/default/files/media_asset/undetectable-untransmittable_en.pdf. Published 2018. Accessed November 1, 2019.
47.
Bagheri  M, Mokri  A, Khosravi  A, Kabir  K.  Effect of abstinence on depression, anxiety, and quality of life in chronic methamphetamine users in a therapeutic community.  Int J High Risk Behav Addict. 2015;4(3):e23903. doi:10.5812/ijhrba.23903PubMedGoogle Scholar
48.
Glasner-Edwards  S, Marinelli-Casey  P, Hillhouse  M, Ang  A, Mooney  LJ, Rawson  R; Methamphetamine Treatment Project Corporate Authors.  Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up.  J Nerv Ment Dis. 2009;197(4):225-231. doi:10.1097/NMD.0b013e31819db6fePubMedGoogle ScholarCrossref
49.
Mahoney  JJ  III, De La Garza  R  II, Jackson  BJ,  et al.  The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders.  Psychiatry Res. 2014;219(2):367-371. doi:10.1016/j.psychres.2014.05.026PubMedGoogle ScholarCrossref
50.
McGregor  C, Srisurapanont  M, Mitchell  A, Wickes  W, White  JM.  Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual.  J Subst Abuse Treat. 2008;35(3):334-342. doi:10.1016/j.jsat.2007.12.003PubMedGoogle ScholarCrossref
51.
Arnsten  JH, Demas  PA, Farzadegan  H,  et al.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.  Clin Infect Dis. 2001;33(8):1417-1423. doi:10.1086/323201PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Data inconsistency, table-header confusion
    Daniel Bloch, MD, FASAM | PrimaryOne Health (Federally-Qualified Health Center)
    Figure 1 shows 241 subjects assessed for eligibility, 153 excluded, 120 randomized; those numbers don't add up
    Table 2 would be easier to understand if the column-2 header were rewritten for each section.
    For example, the first section (Primary Outcomes) could say "Risk Ratio", the second section (Secondary Outcomes) could say "Coefficient", and so forth
    The continuation of Table 2 on page 6 was especially confusing because the header was duplicated as "Risk Ratio or Coefficient" and the true outcome ("No.(%)") was less prominent
    That said, the findings are provocative and give hope for a treatment for this difficult problem.
    CONFLICT OF INTEREST: None Reported
    Original Investigation
    December 11, 2019

    Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial

    Author Affiliations
    • 1San Francisco Department of Public Health, San Francisco, California
    • 2Department of Medicine, University of California, San Francisco, San Francisco
    • 3School of Nursing, University of California, San Francisco, San Francisco
    • 4Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco
    • 5Department of Psychiatry, University of California, San Francisco, San Francisco
    JAMA Psychiatry. 2020;77(3):246-255. doi:10.1001/jamapsychiatry.2019.3655
    Key Points

    Question  Does treatment with mirtazapine reduce the use of methamphetamine and sexual HIV risk behaviors among cisgender men and transgender women who have sex with men?

    Findings  In this analysis, mirtazapine reduced the use of methamphetamine over 24 weeks of treatment and 12 weeks of follow-up after treatment was concluded. Mirtazapine also reduced several sexual HIV risk behaviors; both findings were consistent with a previous study.

    Meaning  Mirtazapine is the first medication to demonstrate efficacy in treating methamphetamine use disorder in 2 independent randomized clinical trials.

    Abstract

    Importance  Methamphetamine use is increasingly prevalent and associated with HIV transmission. A previous phase 2a study of mirtazapine demonstrated reductions in methamphetamine use and sexual risk behaviors among men who have sex with men.

    Objective  To determine the efficacy of mirtazapine for treatment of methamphetamine use disorder and reduction in HIV risk behaviors.

    Design, Setting, and Participants  This double-blind randomized clinical trial of mirtazapine vs placebo took place from August 2013 to September 2017 in an outpatient research clinic in San Francisco, California. Participants were community-recruited adults who were sexually active; cisgender men, transgender men, and transgender women who (1) had sex with men, (2) had methamphetamine use disorder, and (3) were actively using methamphetamine were eligible. Participants were randomized to receive the study drug or placebo for 24 weeks, with 12 more weeks of follow-up. Data analysis took place from February to June 2018.

    Exposures  Mirtazapine, 30 mg, or matched placebo orally once daily for 24 weeks, with background counseling.

    Main Outcomes and Measures  Positive urine test results for methamphetamine over 12, 24, and 36 weeks (primary outcomes) and sexual risk behaviors (secondary outcomes). Sleep, methamphetamine craving, dependence severity, and adverse events were assessed.

    Results  Of 241 persons assessed, 120 were enrolled (5 transgender women and 115 cisgender men). The mean (SD) age was 43.3 (9.8) years; 61 (50.8%) were white, 31 (25.8%) were African American, and 15 (12.5%) were Latinx. A mean (SD) of 66% (47%) of visits were completed overall. By week 12, the rate of methamphetamine-positive urine test results significantly declined among participants randomized to mirtazapine vs placebo (risk ratio [RR], 0.67 [95% CI, 0.51-0.87]). Mirtazapine resulted in reductions in positive urine test results at 24 weeks (RR, 0.75 [95% CI, 0.56-1.00]) and 36 weeks (RR, 0.73 [95% CI, 0.57-0.96]) vs placebo. Mean (SD) medication adherence by WisePill dispenser was 38.5% (27.0%) in the mirtazapine group vs 39.5% (26.2%) in the placebo group (P = .77) over 2 to 12 weeks and 28.1% (23.4%) vs 38.5% (27.0%) (P = .59) over 13 to 24 weeks. Changes in sexual risk behaviors were not significantly different by study arm at 12 weeks, but those assigned to receive mirtazapine had fewer sexual partners (RR, 0.52 [95% CI, 0.27-0.97]; P = .04), fewer episodes of condomless anal sex with partners who were serodiscordant (RR, 0.47 [95% CI, 0.23-0.97]; P = .04), and fewer episodes of condomless receptive anal sex with partners who were serodiscordant (RR, 0.37 [95% CI, 0.14-0.93]; P = .04) at week 24. Participants assigned to mirtazapine had net reductions in depressive symptoms (Center for Epidemiologic Studies Depression Scale score, 6.2 [95% CI, 1.3-11.1] points lower; P = .01) and insomnia severity (Athens score, 1.4 [95% CI, 0.1-2.7] points lower; P = .04) at week 24. There were no serious adverse events associated with the study drug.

    Conclusions and Relevance  In this expanded replication trial, adding mirtazapine to substance use counseling reduced methamphetamine use and some HIV risk behaviors among cisgender men and transgender women who have sex with men, with benefits extending after treatment despite suboptimal medication adherence.

    Trial Registration  ClinicalTrials.gov identifier: NCT01888835

    ×